0
Deep & Emerging Tech·April 15, 2026·1 min read

Could pressure to make money faster kill the next lifesaving pill?

Share

Activist pressure is shortening drug-development time horizons—R&D portfolios are being optimized for near-term cash, not outlier cures. If you’re building tools for biotech, sell on derisking and capital efficiency for late-stage assets, not on enabling moonshot pipelines.